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Abstract
Background: Nε-Carboxymethyllysine (CML) is the major non-cross linking advanced glycation end
product (AGE). CML is elevated in diabetic patients and apparent in atherosclerotic lesions. AGEs are
associated with hypertension and arterial stiffness potentially by qualitative changes of elastic fibers. We
investigated whether CML affects carotid and aortic properties in normoglycemic subjects.
Methods: Hundred-two subjects (age 48.2 ± 11.3 years) of the FLEMENGHO study were stratified
according to the median of the plasma CML level (200.8 ng/ml; 25th percentile: 181.6 ng/ml, 75th percentile:
226.1 ng/ml) into "high CML" versus "low CML" as determined by ELISA. Local carotid artery properties,
carotid intima media thickness (IMT), aortic pulse wave velocity (PWV), blood pressure and fetuin-A were
analyzed. In 26 patients after carotidectomy, CML was visualized using immunohistochemistry.
Results: According to the CML median, groups were similar for anthropometric and biochemical data.
Carotid diameter was enlarged in the "high" CML group (485.7 ± 122.2 versus 421.2 ± 133.2 μm; P < 0.05),
in particular in participants with elevated blood pressure and with "high" CML ("low" CML: 377.9 ± 122.2
μm and "high" CML: 514.5 ± 151.6 μm; P < 0.001). CML was associated fetuin-A as marker of vascular
inflammation in the whole cohort (r = 0.28; P < 0.01) and with carotid diameter in hypertensive subjects
(r = 0.42; P < 0.01). CML level had no effect on aortic stiffness. CML was detected in the subendothelial
space of human carotid arteries.
Conclusion: In normoglycemic subjects CML was associated with carotid diameter without adaptive
changes of elastic properties and with fetuin-A as vascular inflammation marker, in particular in subjects
with elevated blood pressure. This may suggest qualitative changes of elastic fibers resulting in a defective
mechanotransduction, in particular as CML is present in human carotid arteries.
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Introduction
The quality of elastic fibers reflects a hallmark of cardio-
vascular aging and can be affected by the deposition of
interstitial collagen, calcification, lipid peroxidation and
glycoxidation. The latter are induced by advanced glyca-
tion end products (AGEs) which are generated by non-
enzymatic glycation and oxidation of protein and reduc-
ing sugars [1]. Their formation is increased in the blood
and tissues of diabetic subjects as a result of hyperglyc-
emia and is implicated in diabetes-associated vascular
stiffening [1,2]. Nε-Carboxymethyllysine (CML) is the
major non-cross linking AGE, which acts via the receptor
of AGE (RAGE), thereby stimulating proinflammatory
action [3]. In atherosclerotic lesions CML is present in
infiltrating cells, suggesting a role of CML in the develop-
ment of vascular lesions potentially by glycoxidation of
elastin fibers [2].
Circulating levels of AGEs have been measured and
related to the degree of coronary arteriosclerosis in both
diabetic [4] and non-diabetic [5] patients with coronary
artery disease and also to impaired left ventricular func-
tion in patients with type 1 diabetes. Recently McNulty et
al. observed that the concentration of plasma AGEs is sig-
nificantly higher in hypertensive than in normotensive
subjects and related to aortic stiffness independent of age
and blood pressure [6]. Therefore they suggested that
plasma AGEs may play a blood pressure independent role
in vascular remodeling in essential hypertension, in par-
ticular as vascular remodeling is associated with inflam-
mation [7,8] which reflects a major action of AGEs [9].
However, latter results needed to be confirmed in a strict
normoglycemic group and furthermore need to be
extended to carotid artery properties. Based on these
observations we studied the relationship between plasma
CML, carotid and aortic properties, in normoglycemic
subjects. To investigate in how far CML is associated with
vascular inflammatory processes fetuin-A was investigated
as biomarker for vascular inflammation [10,11]. In this
context we furthermore investigated whether fetuin-A
explains carotid diameter changes. Additionally, we inves-
tigated the presence of CML in carotid arteries with
atherosclerotic lesions to link systemic measures with
local function and local CML deposition.
Methods
Hundred-two subjects of the FLEMish study of ENviron-
ment, Genes and Health Outcomes (FLEMENGHO) [12]
involving a random sample of families living in a defined
geographical area in northern Belgium were included in
this study. The Ethics Committee of the University of Leu-
ven and Munich approved the study, respectively. All par-
ticipants gave informed written consent. The inclusion
criteria for the Flemish cohort were participation in a pro-
spective substudy, the age of at least 18 years, no antihy-
pertensive or antihypertensive treatment and
normoglycemia defined as fasting blood sugar below 6.7
mmol/l. The inclusion criteria for the immunohistochem-
istry were atheromatous alteration of the carotid artery in
context with the clinical need of carotidectomy.
For at least 3 h before being examined, the participants
refrained from heavy exercise, smoking, alcohol or caf-
feine-containing beverages. Trained nurses measured
blood pressure and anthropometric characteristics. They
administered a questionnaire to collect information
about each subject's medical history, smoking and drink-
ing habits, and intake of medications. Each participant's
office blood pressure was the average of five consecutive
readings. Elevated blood pressure was a systolic blood
pressure above 140 mmHg and/or 90 mmHg diastolic or
use of antihypertensive treatment. Body mass index (BMI)
was weight in kilograms divided by the square of height in
metres. Nε-Carboxymethyllysine (CML) plasma level of
free CML and protein-bound CML was measured using an
ELISA kit (Microcoat, Bernried, Germany), following the
instructions of the manufacturer. Intra- and interassay var-
iability were below 5%. The entire cohort was grouped
according to the median of plasma CML (median: 200.8,
25th percentile: 181.6, 75th percentile: 226.1). The values
below median are referred to as "low" and these above
median as "high" CML, respectively. Blood glucose, total
cholesterol, HDL, LDL, triglycerides, and serum creatinine
were also measured in all subjects by routine laboratory
methods. Fetuin-A was measured by commercially availa-
ble ELISA according to the manufacturer protocol [13].
By means of a pulsed ultrasound wall-tracking system
(Wall Track System; Pie Medical, Maastricht, The Nether-
lands), 3 trained researchers obtained vascular measure-
ments at the common carotid artery 2 cm proximal of the
carotid bulb. During the ultrasound examination, an
automated oscillometric device (Dinamap 845; Critikon
Inc, Tampa, FL, USA) recorded blood pressure at the
upper arm at 5-minute intervals. As for the conventional
auscultatory measurements, cuff size was adjusted to the
circumference of the upper arm. Standard cuffs had an
inflatable bladder of 12 × 24 cm [14]. As described else-
where, the observers used applanation tonometry with a
pencil-shaped probe (Millar Instruments Inc, Houston,
TX, USA) and calibration to mean arterial pressure and
diastolic blood pressure at the brachial artery to derive the
local pulse pressure at the carotid artery. We computed
cross-sectional compliance (CC) and the distensibility
coefficient (DC) from the diastolic cross-sectional area
(A), the systolic increase in cross-sectional area (ΔA), and
the local pulse pressure (PP): CC=ΔA/PP and DC = (ΔA/
A)/PP. A and ΔA were calculated from diameter (D) and
the change in diameter (ΔD) as A=π(Δ(D/2)2  and
ΔA=πX[(D+ΔD)/2)2-πX(D/2), respectively. The intraob-Cardiovascular Diabetology 2009, 8:45 http://www.cardiab.com/content/8/1/45
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server intrasession variability was <10% for the carotid
measurements. The intraobserver intersession and inter-
observer intrasession variability were of the same order of
magnitude.
The observers also determined carotid-femoral pulse wave
velocity (PWV) from the length of the carotid-femoral seg-
ment and the transit time of the pulse wave. The carotid-
femoral segment was the difference of the distances
between the site of the carotid ultrasound measurement
and the suprasternal notch and between the suprasternal
notch and the site of the femoral measurement. We meas-
ured PWV using a high-fidelity SPC-301 micromanometer
(Millar Instruments, Inc.) interfaced with a laptop compu-
ter running the SphygmoCor software, version 6.31
(AtCor Medical Pty Ltd, Sydney, Australia).
Immunohistochemical CML staining of a carotid artery
with atherosclerotic lesions was performed in human
material after carotidectomy [15]. Twenty six paraformal-
dehyde-fixed, paraffin-embedded tissue sections were cut
(4 μm), dewaxed and rehydrated. After endogenous per-
oxidase blocking (endogenous enzyme block, Dakocyto-
mation, Glostrup, Denmark), slides were incubated with
a 1:100 dilution of CML biotine 0.34 mg/ml antibody,
which was a kind gift by Dr. C. Schalkwijk (University
Maastricht). This was followed by incubation with a 1:400
diluted secondary rabbit anti- mouse IgG HRP antibody
(Serotec, Wiesbaden, Germany) and developed in diami-
nobenzidine tetrahydrochloride (DAB substrate kit for
peroxidase SK-4100; Vector Laboratories, Burlingame, CA,
USA) and counterstained with hematoxylin.
Statistical analyses were performed using SPSS software
version 15.0 (SPSS, Chicago, IL, USA). Comparison
between subjects with above and below the median of
CML was performed by unpaired t-test or the χ2-test. The
Spearman correlation coefficient was assessed for CML
and the clinical properties in the whole cohort and the
subgroup of normotensive and hypertensive subjects.
Results are expressed as mean ± SD. A p value of less than
0.05 was considered to be statistically significant.
Results
Baseline characteristics of the Flemish cohort and accord-
ing to the median plasma CML level of the cohort
(median: 200.8, 25th percentile: 181.6, 75th percentile:
226.1) are given in Table 1. Apart from plasma CML val-
ues no significant difference was present between the
"low" and "high" CML group, in particular no differences
in fasting blood glucose and lipid profile. Thirty-three
subjects had elevated blood pressure level, including 20
with "low" CML and 13 with "high" CML.
Arterial properties according to the total cohort and
according to the median plasma CML level of the cohort
are given in Table 2. Carotid diameter was significantly
larger in the "high" CML group (P < 0.05). PWV was not
different between the "low" and "high" CML group. The
bivariate Spearman association of CML and carotid diam-
eter is for the normotensive cohort r = -0.01 (P = 0.92) and
for subjects with elevated blood pressure r = 0.42 (P <
0.01; Table 3 and Figure 1). Additionally, the role of vas-
cular inflammation was investigated with fetuin-A. CML is
positively associated with fetuin-A (r = 0.28; P < 0.01).
Table 1: Baseline Characteristics according to CML (n = 102, mean ± SD)
Characteristic All CML ≤ Median CML>Median
(n = 51) (n = 51)
Age (y) 48.2 ± 11.3 50.2 ± 11.7 46.8 ± 10.7
Male, female 53/49 26/25 27/24
BMI (kg/m2) 25.8 ± 3.7 25.8 ± 3.7 25.8 ± 3.6
Smoking status 71/31 36/15 35/16
(nonsmokers/smokers)
Brachial SBP (mmHg) 128.4 ± 14.9 128.1 ± 13.2 129.0 ± 16.9
Brachial DBP (mmHg) 82.7 ± 10.5 83.1 ± 9.3 82.4 ± 12.0
Brachial PP (mmHg) 45.8 ± 10.2 45.0 ± 10.0 46.6 ± 10.2
Cholesterol (mmol/L) 5.6 ± 1.0 5.5 ± 1.0 5.8 ± 0.9
HDL (mmol/L) 1.4 ± 0.3 1.3 ± 0.3 1.4 ± 0.3
LDL (mmol/L) 3.4 ± 0.9 3.3 ± 0.9 3.6 ± 0.9
Triglycerides (mmol/L) 2.5 ± 1.4 2.6 ± 1.6 2.2 ± 1.0
Glucose (mmol/L) 5.0 ± 0.7 4.9 ± 0.7 5.0 ± 0.8
Creatinine (μmol/L) 92.0 ± 17.1 93.0 ± 16.0 92.3 ± 17.8
Fetuin (μg/ml) 108.7 ± 52.3 100.8 ± 48.8 115.9 ± 55.2
CML (ng/ml) 210.4 ± 43.7 183.0 ± 12.1 240.7 ± 46.1
CML median: 200.8 ng/ml, Student's t-test and Mann-Whitney-U test where appropriate Bold: P < 0.05
CML: NεCarboxymethyllysine, BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, PP: pulse pressure.Cardiovascular Diabetology 2009, 8:45 http://www.cardiab.com/content/8/1/45
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However Fetuin-A is in not associated with carotid diam-
eter in any group (Figure 1).
Comparing subjects with normal and elevated blood pres-
sure, no difference was apparent with respect to CML and
carotid diameter. However, PWV was significantly ele-
vated in the group with elevated blood pressure (6.5 ± 2.1
versus 7.5 ± 2.4 m/s; P < 0.05; Table 4).
Subdividing the normotensive subjects according to the
CML median no significant differences were apparent for
carotid and aortic properties (data not shown). In con-
trast, subdividing the group with elevated blood pressure
according to the CML median resulted in an increased
carotid diameter in the 13 subjects with "high" CML
(514.5 ± 151.6 μm) as compared to the 20 subjects with
"low" CML (377.9 ± 122.2 μm, P < 0.001; Figure 2), while
the elastic properties as cross-sectional compliance
("high" CML: 0.94 ± 0.33 versus "low" CML: 0.72 ± 0.29
mm2/kPa; P = 0.07) and distensibility ("high" CML: 21.2
± 7.1 versus "low" CML: 18.0 ± 7.3 10-3/kPa; P = 0.20)
were comparable between these two subgroups.
The characteristics of the patients with carotidectomy are
summarized in Table 5. Immunohistochemical staining
of CML in the human carotid artery is shown in Figure 3.
The magnification of 2A  (100×) and 2B (400×) reveal
CML positive cells in the subendothelial space. CML stain-
Association between CML, Fetuin-A and carotid diameter Figure 1
Association between CML, Fetuin-A and carotid diameter. CML and Fetuin-A are positively associated in hypertensive 
(open square) and normotensive (filled black square) subjects (A; r = 0.34 and r = 0.27, respectively). B demonstrates that CML 
is associated with carotid diameter restricted to hypertensive subjects (r = 0.42). C demonstrates that fetuin-A is not associ-
ated with carotid diameter. All correlations are given as calculated by Spearman correlation coefficient. Continuous lines indi-
cate the regression of data represented by open circles and dotted lines those of closed circles.
Table 2: Arterial characteristics (n = 102, mean ± SD)
Characteristics All CML ≤ Median CML>Median
(n = 51) (n = 51)
PWV (m/s) 6.8 ± 2.2 7.2 ± 2.6 6.5 ± 1.7
Common carotid artery
IMT 0.82 ± 0.17 0.82 ± 0.17 0.81 ± 0.18
Diameter, μm 449.0 ± 130.7 421.2 ± 133.2 485.7 ± 122.2
Pulse pressure, mm Hg 45.0 ± 8.9 44.8 ± 9.2 45.6 ± 8.7
CC, mm2/kPa 0.91 ± 0.33 0.85 ± 0.32 0.98 ± 0.34
DC, 10-3/kPa 22.5 ± 8.4 21.4 ± 8.8 23.7 ± 8.0
CML median: 200.8 ng/ml, Student's t-test and Mann-Whitney-U test where appropriate Bold: P < 0.05
CML: NεCarboxymethyllysine, PWV: pulse wave velocity, IMT: intima media thickness, CC: cross-sectional compliance, DC: distensibility coefficientCardiovascular Diabetology 2009, 8:45 http://www.cardiab.com/content/8/1/45
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ing is present in atheromatous lesions and colocalizes
with inflammatory cells.
Discussion
The main finding of this study is that carotid enlargement
is apparent in context with elevated CML plasma levels
which are still in the normal range. Moreover, the effect of
CML on carotid enlargement is predominantly present in
subjects with elevated blood pressure without changes in
cross-sectional compliance or distensibility. Finally, CML
was associated with fetuin-A as vasculo-inflammatory
marker and was present in the subendothelial space of
human carotid arteries.
CML is involved in vascular stiffening of type 1 diabetics
as well as of hypertensive subjects [6,16]. Our study dem-
onstrates that carotid enlargement is apparent in this
cohort of normoglycemic subjects. This is particularly
striking in subjects with hypertensive blood pressure val-
ues, where CML demonstrated an independent associa-
tion with carotid diameter. Moreover, the shown effect is
already present at a CML range below levels obtained in
diabetes or renal insufficiency [17,18].
Although no prospective data exist on carotid diameter,
Kawamoto et al. showed that the carotid artery diameter
correlates with conventional cardiovascular risk factors
including alcohol consumption [19], these findings sug-
gest that the carotid artery diameter may reflect the ability
of adaptive remodeling to the atherosclerosis before
plaque formation. Moreover, increased carotid artery
diameter as consequence of arterial stiffness limits the
deterioration of the buffering capacity of the central artery
[20]. Thus, CML can be an important factor during the
development of atherosclerosis and may be relevant in
clinical risk assessment. As atherosclerosis is driven by
inflammation, we additionally assessed fetuin-A as
marker for vascular inflammation [21,22]. In this context,
we observed and association between fetuin-A and CML
throughout the whole cohort. This suggests that CML
potentially reflects the state of vascular inflammation
[23]. This is further strengthened by our observation of
CML in the subendothelial space of atherosclerotic
human carotid artery material which is in line with previ-
ous descriptions in human aortic valves [24].
The mechanisms underlying this CML-related effect on
carotid diameter cannot primarily be explained by an
enhanced cross linking by AGEs as CML may affect the
properties of the AGE-modified proteins but does not
cause cross-linking in or between proteins [25,26]. There-
fore, our findings suggest that the effect of CML on arterial
diameter involves mechanisms other than cross-linking,
such as ligation of the receptor for AGE (RAGE) [27].
RAGE is highly expressed in the endothelium of activated
vessels [28]. Furthermore, CML is a ligand for RAGE [29].
Table 3: Association between CML and clinical characteristics of the whole cohort, normotensive and hypertensive subjects
Total cohort Normotension Hypertension
rP   value rP   value rP   value
Age -0.17 0.10 -0.13 0.29 -0.17 0.34
Sex -0.04 0.76 -0.15 0.24 0.19 0.30
BMI 0.05 0.60 0.01 0.99 0.17 0.33
Smoking 0.03 0.75 -0.02 0.88 0.05 0.78
SBP 0.02 0.81 0.09 0.46 0.30 0.09
DBP -0.05 0.58 -0.04 0.73 0.17 0.34
PP 0.12 0.22 0.14 0.26 0.16 0.37
Creatinine -0.10 0.37 -0.03 0.82 -0.11 0.54
Glucose 0.05 0.61 -0.08 0.55 0.13 0.46
Cholesterol 0.20 0.05 0.23 0.06 0.15 0.40
HDL 0.17 0.08 0.08 0.53 0.31 0.07
LDL 0.21 0.04 0.27 0.03 0.15 0.41
Triglycerides -0.07 0.52 -0.04 0.71 -0.09 0.63
Fetuin 0.28 0.01 0.27 0.03 0.34 0.04
PWV -0.12 0.23 -0.20 0.10 0.06 0.75
Common carotid artery
IMT 0.08 0.45 0.15 0.25 -0.06 0.72
Diameter 0.18 0.07 -0.01 0.93 0.42 0.01
Pulse pressure 0.10 0.34 0.09 0.48 0.18 0.31
CC 0.12 0.26 -0.07 0.56 0.26 0.14
DC 0.11 0.30 0.01 0.99 0.21 0.23
Spearman correlation coefficient Bold: P < 0.05
CML: NεCarboxymethyllysine, BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, PP: pulse pressure, PWV: pulse 
wave velocity, IMT: intima media thickness, CC: cross-sectional compliance, DC: distensibility coefficientCardiovascular Diabetology 2009, 8:45 http://www.cardiab.com/content/8/1/45
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Binding of circulating CML modified proteins to RAGE
activates extracellular-regulated kinase 1/2 (ERK1/2),
nuclear factor κ-B, secretion of proinflammatory
cytokines, and modulates gene expression in several cell
types, such as monocytes, endothelial cells, and vascular
smooth muscle cells [30]. This may lead to changes in the
production of extracellular matrix proteins, such as colla-
gen and elastin structure, and alterations in vascular elas-
ticity [31,32], as obtained by glycoxidation, and lipid
peroxidation [24]. Because CML can be formed by glycox-
idation and lipid peroxidation [2], the association of
carotid diameter with CML may reflect the involvement of
increased oxidative stress in arterial remodelling [33]
which is further strengthened by the association with
fetuin-A. However, as the serum concentration of soluble
RAGE is in the picomolar range [34] whereas the CML
molaritiy is in the micromolar range, it is questionable
that sRAGE/CML binding occurs in vivo and has any bio-
logical effect. In this respect, serum CML is more likely an
Table 4: Baseline Characteristics according to blood pressure (n 
= 102, mean ± SD)
Characteristic Normal BP Elevated BP
(n = 69) (n = 33)
Age (y) 47.0 ± 10.5 50.6 ± 12.7
Male, female 36/33 17/16
BMI (kg/m2) 25.5 ± 3.5 26.3 ± 3.9
Non-Smokers/Smokers 49/20 22/11
Brachial SBP (mmHg) 121.5 ± 8.7 142.2 ± 15.0
Brachial DBP (mmHg) 78.1 ± 6.9 92.0 ± 10.5
Cholesterol (mmol/L) 5.6 ± 1.0 5.6 ± 0.9
HDL (mmol/L) 1.4 ± 0.4 1.4 ± 0.3
LDL (mmol/L) 3.4 ± 0.9 3.4 ± 0.9
Triglycerides (mmol/L) 2.4 ± 1.2 2.5 ± 1.6
Glucose (mmol/L) 5.0 ± 0.7 4.8 ± 0.8
Creatinine (μmol/L) 91.6 ± 15.8 91.6 ± 15.2
Fetuin (μg/ml) 110.0 ± 53.2 106.1 ± 51.4
CML (ng/ml) 214.2 ± 46.6 209.3 ± 40.7
PWV (m/s) 6.5 ± 2.1 7.5 ± 2.4
Common carotid artery
IMT 0.81 ± 0.16 0.84 ± 0.19
Diameter, μm 458.5 ± 121.1 430.1 ± 148.1
Pulse pressure, mm Hg 42.9 ± 7.7 49.2 ± 9.8
CC, mm2/kPa 0.96 ± 0.32 0.80 ± 0.32
DC, 10-3/kPa 24.0 ± 8.5 19.2 ± 7.3
Student's t-test and Mann-Whitney-U test where appropriate Bold: P 
< 0.05, CML: NεCarboxymethyllysine, BMI: body mass index, SBP: 
systolic blood pressure, DBP: diastolic blood pressure, PWV: pulse 
wave velocity, IMT: intima media thickness, CC: cross-sectional 
compliance, DC: distensibility coefficient
Carotid diameter in subjects with elevated blood pressure (n  = 33) according to the CML median Figure 2
Carotid diameter in subjects with elevated blood 
pressure (n = 33) according to the CML median. 
Carotid diameter was significantly lower in 20 subjects with 
"low" CML (377.9 ± 122.1 μm) as compared to the 13 sub-
jects with "high" CML (514.5 ± 151.7 μm; P < 0.001).
Representative immunohistochemical staining of CML in the  human carotid artery Figure 3
Representative immunohistochemical staining of 
CML in the human carotid artery. The magnification of 
2A (100×) and 2B (400×) reveal CML positive cells in the 
subendothelial space.
Table 5: Characteristics of patients with carotidectomy
Characteristic Carotidectomy (n = 26)
Age (y) 73.0 ± 8.4
Male, female 18/8
BMI (kg/m2) 26.6 ± 4.5
Smokers/Non-smokers 10/16
Brachial SBP (mmHg) 139.4 ± 14.3
Brachial DBP (mmHg) 77.4 ± 6.3





eGFR (ml/min) 65.3 ± 22.1
Present CVD (y/n) 6/20
CRP 0.65 ± 0.48Cardiovascular Diabetology 2009, 8:45 http://www.cardiab.com/content/8/1/45
Page 7 of 8
(page number not for citation purposes)
indicator of a dysfunctional cellular metabolism in the
vascular wall in particular as we demonstrated CML dep-
osition in atheromatous lesions of the carotid artery.
CML had no effect on carotid enlargement in subjects
with normotensive blood pressure values. By contrast, in
subjects with elevated blood pressure the CML plasma
level characterized the extent of carotid enlargement with-
out adaptive changes of the elastic artery properties. This
may in turn lead to increased circumferential wall stress
and consecutively result in a potentially defective mech-
anotransduction, that is, the control of smooth muscle
cell growth and migration, and production of extracellular
matrix in response to diameter enlargement [35]. Further-
more, a direct effect on elastin may be considered as CML
co-localizes with elastin [36] and results in fenestration of
elastic laminae [37].
In this cohort no effect of CML on PWV was observed.
Therefore this study contrasts a recent observation
describing CML as blood pressure independent factor in
aortic stiffness [6]. However, there are important differ-
ences between both studies. Firstly, in the latter study AGE
measurement was performed using a non-selective ELISA
detecting other AGEs than CML as well, while in our study
a specific ELISA for CML was used [38]. Secondly, blood
glucose levels were elevated in the hypertensive group of
McNulty et al., suggesting a more general glucose effect on
both CML level and stiffness complicating the detection of
the effects of AGEs alone. By contrast, our study excluded
subjects with a fasting blood sugar of >6.7 mmol/l.
In summary, normoglycemic subjects with higher CML
plasma levels are characterized by carotid enlargement
without changes in elastic properties, in particular in ele-
vated blood pressure. This may be associated with a qual-
itative change of elastic fibers and may lead to a defective
mechanotransduction both explainable by local glycoxi-
dation and lipid peroxidation induced inflammation.
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